Type 1 diabetic cardiomyopathy in the Akita (Ins[2.sup.WT/C96Y]) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function

Basu R, Oudit GY, Wang X, Zhang L, Ussher JR, Lopaschuk GD, Kassiri Z. Type 1 diabetic cardiomyopathy in the Akita (Ins[2.sup.WT/C96Y]) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function. Am J Physiol Heart Circ Physiol 297: H2096-H2108, 2009. First published October 2, 2009; doi: 10.1152/ajpheart.00452.2009.--Diabetic cardiomyopathy is an important contributor to diastolic and systolic heart failure. We examined the nature and mechanism of the cardiomyopathy in Akita (Ins[2.sup.WT/C96Y]) mice, a model of genetic nonobese type 1 diabetes that recapitulates human type 1 diabetes. Cardiac function was evaluated in male Ins[2.sup.WT/C96Y] and their littermate control (Ins[2.sup.WT/WT]) mice using echocardiography and tissue Doppler imaging, in vivo hemodynamic measurements, as well as ex vivo working heart preparation. At 3 and 6 mo of age, Ins[2.sup.WT/C96Y] mice exhibited preserved cardiac systolic function compared with Ins[2.sup.WT/WT] mice, as evaluated by ejection fraction, fractional shortening, left ventricular (LV) end-systolic pressure and maximum rate of increase in LV pressure in vivo, cardiac work, cardiac power, and rate-pressure product ex vivo. Despite the unaltered systolic function, Ins[2.sup.WT/C96Y] mice exhibited significant and progressive diastolic dysfunction at 3 and 6 mo of age compared with Ins[2.sup.WT/WT] mice as assessed by tissue and pulse Doppler imaging (E-wave velocity, isovolumetric relaxation time) and by in vivo hemodynamic measurements (LV end-diastolic pressure, time constant of LV relaxation, and maximum rate of decrease in LV pressure). We found no evidence of myocardial hypertrophy or fibrosis in the Ins[2.sup.WT/C96Y] myocardium. Consistent with the lack of fibrosis, expression of procollagen-[alpha] type I, procollagen-[alpha] type III, and fibronectin were not increased in these hearts. Ins[2.sup.WT/C96Y] hearts showed significantly reduced sarcoplasmic reticulum [Ca.sup.2+]-ATPase 2a (cardiac sarcoplasmic reticulum [Ca.sup.2+] pump) levels, elevated [beta]-myosin heavy chain isoform, increased long-chain fatty acids, and triacylglycerol with evidence of lipotoxicity, as indicated by a significant rise in ceramide, diacylglycerol, and lipid deposits in the myocardium. Consistent with metabolic perturbation, and a switch to fatty acid oxidation from glucose oxidation in Ins[2.sup.WT/C96Y] hearts, expression of mitochondrial long-chain acyl-CoA dehydrogenase and pyruvate dehydrogenase kinase isoform 4 were increased. Insulin treatment reversed the diastolic dysfunction, the elevated B-type natriuretic peptide and [beta]-myosin heavy chain, and the reduced sarcoplasmic reticulum [Ca.sup.2+]-ATPase 2a levels with abolition of cardiac lipotoxicity. We conclude that early type 1 diabetic cardiomyopathy is characterized by diastolic dysfunction associated with lipotoxic cardiomyopathy with preserved systolic function in the absence of interstitial fibrosis and hypertrophy. insulin; fibrosis; hypertrophy; sarco(endo)plasmic reticulum calcium-ATPase 2a doi: 10.1152/ajpheart.00452.2009